Among the various events that have contributed to the development of private equity in Asia over the 30 years since AVCJ was established, three stand out as particular game changers
Digging deep into our archives in preparation for the 30th anniversary of the establishment of AVCJ has offered numerous insights into how much Asian private equity and venture capital has evolved over...
Even if pan-Asian buyout firms aren't actively pursuing investments in internet-related businesses, they cannot ignore the potential disruptive impact of these technologies on other portfolio companies
Mekong Capital's 6.3x return on its investment in Vietnam-based pharmaceuticals player Traphaco involved turning the company's distribution model on its head, as well as supporting expansion and improving governance
China Renaissance has added dedicated healthcare and mezzanine debt strategies to its existing growth-stage private equity offering as part of efforts to more than treble its assets under management (AUM) over the next three years.
China Venture Capital Fund, a VC vehicle backed by the Chinese government, and ChinaEquity Group have jointly led a RMB670 million ($101 million) round for 3D Medicines, which focuses on personalized diagnostics and treatment for cancer.